Powder: -20°C for 3 years | In solvent: -80°C for 1 year
JNJ- 10198409 is a relatively selective and ATP competitive PDGF-RTK inhibitor (IC50=2 nM). JNJ-10198409 has good activity against PDGFR-β kinase (IC50=4.2 nM) and PDGFR-α kinase (IC50=45 nM). It is a dual-mechanism, antiangiogenic, and tumor cell antiproliferative agent.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 47.00 | |
5 mg | In stock | $ 147.00 | |
10 mg | In stock | $ 218.00 | |
25 mg | In stock | $ 369.00 | |
50 mg | In stock | $ 543.00 | |
100 mg | In stock | $ 776.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 176.00 |
Description | JNJ- 10198409 is a relatively selective and ATP competitive PDGF-RTK inhibitor (IC50=2 nM). JNJ-10198409 has good activity against PDGFR-β kinase (IC50=4.2 nM) and PDGFR-α kinase (IC50=45 nM). It is a dual-mechanism, antiangiogenic, and tumor cell antiproliferative agent. |
Targets&IC50 | PDGFRβ:4.2 nM, PDGFRα:45 nM |
In vitro | JNJ-10198409 has effective antiproliferative activity in six of eight human tumor cell lines (IC50<0.033 μM). It also is a potent inhibitor of the c-Abl kinase (IC50: 22 nM) [1,2]. |
Synonyms | JNJ-10198409 |
Molecular Weight | 325.34 |
Formula | C18H16FN3O2 |
CAS No. | 627518-40-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 83.33 mg/mL (256.13 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
JNJ-10198409 627518-40-5 Angiogenesis Tyrosine Kinase/Adaptors PDGFR Platelet-derived growth factor receptor JNJ 10198409 inhibit JNJ-10198409 Inhibitor JNJ10198409 inhibitor